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S1. The Effects Of Obesity And Smoking On The Function 
Of Natural Killer Cells In Psoriasis
AM Tobin, L Lynch, A Kwasnik, S Rogers, P Collins, D 
O’Shea, B Kirby.
Department of Dermatology and Obesity Research Group, St 
Vincent’s Hospital, Dublin.
Obesity has emerged as a major co-morbidity in patients with 
psoriasis. In a case control study we found that patients with 
psoriasis had significantly higher body mass indices (BMI) 
compared to controls (p = 0.004). Increased adiposity and 
weight gain were strong risk factors for the development of 
psoriasis in the Nurses Health study1. Multivariate analysis 
demonstrated a clear, graded association between BMI and 
the risk of having psoriasis1.
Adipose tissue actively secretes cytokines such as TNF-alpha 
and interleukin-6 and pro-inflammatory adipokines such as 
leptin  and  resistin  along  with  adiponectin  which  has  anti-
inflammatory effects. Patients with psoriasis had raised levels 
of serum resistin compared to controls2. Serum levels were also 
correlated with psoriasis disease activity and were unrelated 
to BMI suggesting a link between psoriasis and adipokines. 
A  second  study  of  39  patients  found  disease  severity  was 
correlated with insulin resistance and serum resistin.
Recent studies have shown that patients who are obese have 
lower  levels  of  natural  killer  (NK)  cells  when  compared 
to  controls.  Natural  killer  cells  from  obese  patients  also 
had decreased levels of in-vitro activity compared to lean 
controls. Natural killer cells are thought to be involved in the 
pathogenesis of psoriasis and patients have lower levels of 
circulating NK cells than controls.
We have investigated levels of circulating NK cells in obese 
and lean patients with psoriasis, their in vitro cytotoxcicity 
and  also  the  effect  of  the  adipokines  leptin,  adiponectin, 
resistin and cigarette smoke extract on the cytotoxcicity of 
circulating NK cells.
CD 56; a marker of NK and NK-T cells; cells have been 
extracted  from  peripheral  blood  monocytes  (PBMCs)  of 
patients with psoriasis with magnetic beads. Using ethidium 
bromide and UV microscopy these CD 56 cells were counted.   
Psoriasis patients who are obese, defined as BMI > 30 (N = 
6) have on average 3.84% CD 56 of total PBMCs cells versus 
patients who are lean defined as BMI < 25 (N = 7) have on 
average 8.9% CD56 cells (p = 0.02).
CD  56  cells  isolated  above  from  PBMCs  of  patients 
with  psoriasis  and  also  controls  were  incubated  with  the 
myelogenous  tumour  line  K562  in  the  presence  of  the 
adipokines resistin, leptin and adiponectin and also cigarette 
smoke  extract  for  four  hours.  Using  7-AAD  staining, 
the numbers of killed tumour cells were counted by flow 
cytometry and gating on the tumour cells.
In the presence of resistin tumour killing by CD 56 cells 
was increased by on average 28% when compared to CD 56 
cells alone in six patients with psoriasis (p = 0.08). In the 
presence of cigarette smoke extract the killing of CD 56 cells 
was decreased by on average 38 % in eleven patients with 
psoriasis (p = 0.001).
These results indicate a possible mechanism whereby obesity 
affects  psoriasis  by  further  lowering  NK  cells. They  also 
indicate that resistin and smoking may exacerbate this NK 
defect. By stimulating NK cells resistin may be hastening 
their apoptosis and cigarette smoke appears to be having a 
directly toxic effect. 
1.   Arathi RS, Curhan G, Hyon CK.  Arch Intern Med 2007;176:13-27. 2. 
Johnston A, Arnadottir S, Gudjonsson, et al. Br J Dermatol 2008;159:342-
350.
S2. An audit to evaluate service outcome in children with 
Atopic Eczema attending a paediatric dermatology clinic.
C Devereux, K McKenna, A Bingham, S Hoey
Royal Belfast Hospital for Sick Children, Belfast. 
A re-audit was conducted to determine if the service provided 
at a paediatric dermatology out-patient clinic met the working 
standards for the management of atopic eczema as defined 
by  the  BAD.   The  re-audit  results  were  compared  to  the 
results from the BAD Audit of atopic eczema management in 
secondary care, Phase 3: Audit of Service outcome, published 
in  2000.  This  audit  was  a  prospective  study  of  patients 
quality of life and disability preconsultation and 6 weeks 
postconsultation.  Standards set were:
1.   Of patients reporting sleep loss secondary to eczema, at least 70% 
should report a favourable change at 6 weeks.
2.   There should be a 25% relative improvement in the CDLQI in 60% of 
patients within 6 weeks.
3.   The management process should improve the worst aspect of the disease 
for 80% of patients.© The Ulster Medical Society, 2009.
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4.   Of those patients who are away from school because of their atopic 
eczema, 80% should return to school within 6 weeks following their 
initial assessment. 
Standards were evaluated using 2 questionnaires offered to 
all new patients with a diagnosis of atopic eczema attending 
paediatric  dermatology  clinics  from  January-June  2008. 
Questionnaire 1 was completed at baseline.  Questionnaire 
2 was sent by post to the part 1 recruits 6 weeks after their 
initial consultations. 
42 completed Part 1 and 27 completed Part 2 questionnaires 
were collected, amounting to an overall 64% response rate 
versus 67% response rate observed in the original audit.
Improvement in sleep loss at 6 weeks was attained in 52% 
of  cases  (standard  set  70%). There  was  a  >25%  relative 
improvement in CDLQI score in 56% of patients falling short 
of the 60% standard set. Improvement in the worst aspect of 
disease was achieved in 67% cases, again not attaining the 
80% standard set.
The 2008 re-audit results reveal more favourable outcomes 
compared to the original results in 2000, although fall short 
of the standards set. Are original working standards set too 
high? Is 6 weeks the optimum time to measure improvement 
in outcome?  If non-responders did not reply because they 
had improved, the working standards may have been achieved.
Several  recommendations  have  arisen  following  review 
of these results.  These include inviting all new patients to 
complete a CDLQI; to identify for each individual what is 
the most troublesome aspect of their disease and re-evaluate 
at follow up and finally to avail of the input of a paediatric 
dermatology nurse specialist for all patients
S3. Merkel Cell Polyomavirus (MCV) – a new skin cancer 
virus.
WL Ho1, M Carr 2, W Hall 2, GM Murphy 1
1Department of Dermatology, Beaumont Hospital, Dublin, 
2National Viral Reference Laboratory, UCD, Dublin.
Merkel cell carcinoma (MCC) is a rare and aggressive human 
skin cancer of neuroendocrine origin, with a high mortality 
and  an  increasing  incidence  worldwide.  It  predominantly 
affects  elderly  and  immunocompromissed  individuals,  a 
feature suggestive of an infectious origin. In early 2008, Feng 
et al described the presence of a novel virus in Merkel cell 
carcinomas (MCC)1. Viral DNA was integrated within tumour 
genome in a clonal pattern in 8 out of 10 MCC samples, 
suggesting that MCV infection and clonal integration may 
be  the  contributing  factor  in  the  pathogenesis  of  MCC. 
Another study compared MCC tumours from an American 
cohort of MCC to an Australian cohort, which demonstrated 
a much higher prevalence of the virus in the American cohort, 
69% vs. 24%2,3. The regional difference suggests that there 
may be variable contributions of UV radiation and MCV to 
oncogenesis. 
Our aim was to evaluate the percentage prevalence of MCV 
in MCCs to further substantiate the above findings, in our 
Irish cohort. We identified 7 patients who had Merkel cell 
carcinoma,  3  of  whom  were  renal  transplant  recipients. 
Nucleic acid was extracted from the MCC tumour samples 
and real-time and end point PCR was carried out to determine 
the percentage positivity. 
Results showed 29% positivity in the detection of MCV in 
these tumours, in keeping with the findings of the Australian 
cohort. Deletion of viral elements and/or disruption of human 
tumour  suppressor  genes  could  conceivably  contribute  to 
uncontrolled cell growth. The highly related polyomavirus 
SV40 large tumour antigen is known to bind p53 and pRb 
which are both tumour suppressors and thus contribute to 
tumourigenesis by cell cycle deregulation. The two previously 
characterized  MCV  integration  events  by  Fend  et  al  lead 
to disruption these tumour suppressor regions in the MCV 
genome.
The role of MCV in the pathogenesis of MCCs of the skin and 
other neuroendocrine tumours has yet to be fully elucidated, 
but ongoing studies should provide new evidence in the near 
future.
1.   Feng H, Shuda M, Chang  Y, Moore PS Clonal Integration of Polyomavirus 
in Human merkel Cell Carcinoma. Science 2008;319(5866):1096-1100.   
2.   Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, Zur 
Hausen A. Frequent Detection of Merkel Cell Polyomavirus in Human 
Merkel Cell Carcinomas and Identification of a unique Deletion in the 
VP1 Gene. Cancer Res 2008;68(13):5009-13.  
3.   Garneski KM, DeCaprio JA, Nghiem PJ.  Merkel Cell Polyomavirus 
Is More Frequently Present in North American than Australian Merkel 
Cell Carcinoma Tumors. Invest Dermatol 2008.
S4. Aberrant DNA methylation is linked with MTHFR 
C677T genetic polymorphism in cutaneous SCC. 
ME Laing, R Cummins*, EW Kay*, GM Murphy. 
Departments  of  Dermatology  and  *Molecular  Pathology, 
Beaumont Hospital, Dublin.  
Changes  in  genomic  DNA  methylation  associated  with 
cancer  include  global  DNA  hypomethylation  and  gene 
specific  hypermethylation.  We  have  recently  identified 
a  genetic  variant  in  the  MTHFR  gene  involved  in  the 
methylation pathway which confers risk for the development 
of  squamous  cell  carcinoma  in  renal  transplant  patients1. 
This genetic variant has also been discovered to confer risk 
in non transplant patients with low folate status  2.    Our 
aim in this study was to evaluate global and gene specific 
methylation  status  in  SCC  and  non  neoplastic  skin  in 
renal transplant patients and correlate this to the MTHFR 
polymorphism. We evaluated 87 skin samples in this study, 
including SCC and adjacent non neoplastic skin from 33 
patients. Seventeen patients had the MTHFR polymorphism, 
16 had no MTHFR polymorphism. SCC and non neoplastic 
skin were microdissected from paraffin blocks. DNA was 
extracted. PCR was carried out for specific genes p16 and 
MGMT and also LINE 1 which reflects global methylation. 
Quantitative evaluation of methylation levels was carried out 
by pyrosequencing after bisulphite modification of samples.   
Methylation analysis was evaluable in 40 SCCs and 36 non 
neoplastic skin samples. Global hypomethylation was evident 
in SCCs compared to adjacent non neoplastic skin (p<0.04). 
Patients with the MTHFR polymorphism had higher levels of 
methylation in tumours and non neoplastic skin compared to 
those without the MTHFR polymorphism (p < 0.002).  Global 
hypomethylation appears to be a feature of SCC. Aberrant © The Ulster Medical Society, 2009.
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methylation of DNA appears related to polymorphisms of 
MTHFR. In this study we found a functional effect of the 
MTHFR polymorphism significantly related to methylation 
of DNA. This might indicate that patients with the MTHFR 
polymorphism have an overall dysregulation of methylation 
in the genome of cancer and non neoplastic tissue. Together 
these  findings  suggest  that  intervention  in  the  form  of 
demethylating  agents  or  folate  supplementation  may  be 
beneficial in the treatment or prevention of SCC .
1.   Laing ME et al. Association of methylenetetrahydrofolate reductase 
polymorphism  and  the  risk  of  squamous    cell  carcinoma  in  renal 
transplant patients. Transplantation 2007;84(1):113-6.  2. Han J et al. 
Polymorphisms in the MTHFR and VDR genes and skin cancer risk. 
Carcinogenesis 2007;28(2):390.
S5. The effect of isotretinoin on depressive symptoms in 
patients with acne vulgaris – a prospective cohort study 
1999-2007 
D O’Kane1, A O’Hagan2, A McGovern3, J Dougherty4, H 
Acheson1,  K  McKenna1,  JR  Corbett,  DK Armstrong,  M 
Parker5, C Kelly4, C McMillan1 
1Departments of Dermatology and 4Psychiatry, Belfast City 
Hospital.  2Departmenta  of  Dermatology  and  3Psychiatry, 
Craigavon Area Hospital. 5Clinical Research Support Centre, 
Royal Victoria Hospital, Belfast.  
Oral isotretinoin is an effective treatment for severe acne 
unresponsive to conventional therapies.  Concerns remain 
over the drug’s safety profile and in particular its effect on 
mood status.   
We designed a prospective cohort study to investigate the 
role of isotretinoin on mood status in patients with acne. 
Consenting patients initiating isotretinoin therapy completed 
a pre-treatment generic questionnaire and a modified Beck 
Depression Inventory (BDI) at week 0, 4, 16, and 4 weeks 
post-treatment.  The  BDI  was  composed  of  twenty-one 
questions,  each  answer  being  a  score  of  0-3,  depending 
on severity. All patients were treated with 0.5-1mg/kg of 
isotretinoin per day in two divided doses for 16-20 weeks. 
486 patients were deemed eligible for inclusion, 58% male, 
with  a  mean  (standard  deviation)  age  of  21  (5.9).  The 
overall trend was a decrease in BDI scores, with significant 
differences at all stages of treatment. Compared to baseline, 
the  mean  change  in  BDI  was  -0.43  (p=0.02)  at  week  4 
(n=474), -0.628 (p=0.003) at week 16 (n=341), and -0.945 
(p<0.0001) 4 weeks post-treatment (n=183). No increased 
risk of depression was identified in those individuals with 
baseline depressive symptoms (indicated by a baseline BDI 
≥10), or a documented personal/family history of depression. 
A review of medical notes and pharmacy records revealed 
that 2 of the 486 patients (0.4%) discontinued isotretinoin 
after developing mild depressive symptoms. Both reported 
an  improvement  in  mood  status  following  cessation  of 
isotretinoin. There were no reports of deliberate self-harm, 
attempted or completed suicide, during treatment or follow-
up. A further patient discontinued treatment in response to 
rectal bleeding.
As  far  as  we  are  aware,  this  is  the  largest  prospective 
study investigating the effect of isotretinoin on depressive 
symptoms.  No  evidence  of  a  causal  relationship  between 
isotretinoin  use  and  depression  was  identified.  Mild 
depressive symptoms occurring in <1% of patients may reflect 
an idiosyncratic side-effect or be unrelated to isotretinoin.  
It  is  difficult  to  conclusively  exclude  a  link  between 
isotretinoin and depression due to the confounding influence 
of  acne  and  the  risk  of  depression  among  the  general 
population. Utilising a depression score such as the BDI when 
prescribing isotretinoin encourages dermatologists to monitor 
depressive symptoms, regardless of whether there is a causal 
relationship to the drug or not. 